ATE195553T1 - Kristallisierung von m-csf - Google Patents

Kristallisierung von m-csf

Info

Publication number
ATE195553T1
ATE195553T1 AT93915279T AT93915279T ATE195553T1 AT E195553 T1 ATE195553 T1 AT E195553T1 AT 93915279 T AT93915279 T AT 93915279T AT 93915279 T AT93915279 T AT 93915279T AT E195553 T1 ATE195553 T1 AT E195553T1
Authority
AT
Austria
Prior art keywords
csf
antagonists
directed
agonists
crystallization
Prior art date
Application number
AT93915279T
Other languages
German (de)
English (en)
Inventor
Jayvardhan Pandit
Jarmila Jancarik
Sung-Hou Kim
Kirston Koths
Robert Halenbeck
Anna Lisa Fear
Eric Taylor
Ralph Yamamoto
Andrew Bohm
Original Assignee
Chiron Corp
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp, Univ California filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE195553T1 publication Critical patent/ATE195553T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT93915279T 1992-06-09 1993-06-09 Kristallisierung von m-csf ATE195553T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89651292A 1992-06-09 1992-06-09
PCT/US1993/005548 WO1993025687A1 (en) 1992-06-09 1993-06-09 Crystallization of m-csf

Publications (1)

Publication Number Publication Date
ATE195553T1 true ATE195553T1 (de) 2000-09-15

Family

ID=25406334

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93915279T ATE195553T1 (de) 1992-06-09 1993-06-09 Kristallisierung von m-csf

Country Status (7)

Country Link
US (2) US5866114A (enExample)
EP (2) EP0955365A3 (enExample)
JP (2) JPH08507916A (enExample)
AT (1) ATE195553T1 (enExample)
CA (1) CA2137793C (enExample)
DE (1) DE69329247T2 (enExample)
WO (1) WO1993025687A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
CA2249007A1 (en) * 1996-03-14 1997-09-18 Takeshi Shibuya Parasite-derived anti-inflammatory immunomodulatory protein
WO2001034177A2 (en) * 1999-11-08 2001-05-17 The Government Of The United States Of America, A S Represented By The Secretary, Department Of Hea Lth & Human Services, The National Institutes Of Health Method of treating a viral infection using antagonists of macrophage colony stimulating factor
CN100439397C (zh) 2001-02-09 2008-12-03 基因技术股份有限公司 Igf-1的结晶
US7247618B2 (en) * 2001-04-30 2007-07-24 Tripathi Rajavashisth Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
ATE468862T1 (de) 2001-07-11 2010-06-15 Maxygen Inc G-csf konjugate
US7563595B2 (en) * 2002-11-08 2009-07-21 University Of South Florida Nucleic acids encoding functional splice variants of the α7 nicotinic acetylcholine receptor subunit and methods for producing the encoded proteins
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
WO2005057169A2 (en) * 2003-12-05 2005-06-23 Trellis Bioscience, Inc. Homogeneous competition assays
WO2005070447A2 (en) * 2004-01-21 2005-08-04 Chiron Corporation M-csf muteins and uses thereof
US20060094081A1 (en) * 2004-10-22 2006-05-04 Carsten Schubert Crystal structure of the c-fms kinase domain: applications and use of heterologous substitutions of kinase insert domains for crystallization
US7381805B2 (en) 2005-06-01 2008-06-03 Maxygen Holdings, Ltd. Compositions comprising mixtures of positional PEG isomers of PEGylated G-CSF
KR100970770B1 (ko) 2008-02-12 2010-07-16 한국기초과학지원연구원 결정성 재조합 단백질 휴먼 에스피오티 및 이의 결정화방법
US8183207B2 (en) * 2008-11-26 2012-05-22 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
US8080246B2 (en) * 2008-11-26 2011-12-20 Five Prime Therapeutics, Inc. Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules
AR075899A1 (es) * 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
EP2949670B1 (en) 2009-12-10 2019-02-27 F. Hoffmann-La Roche AG Antibodies binding preferentially human csf1r extracellular domain 4 and their use
KR101656548B1 (ko) 2010-03-05 2016-09-09 에프. 호프만-라 로슈 아게 인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도
JP5989547B2 (ja) 2010-03-05 2016-09-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトｃｓｆ−１ｒに対する抗体及びその使用
SMT201900074T1 (it) 2010-05-04 2019-02-28 Five Prime Therapeutics Inc Anticorpi che legano csf1r
US20140378537A1 (en) 2011-09-09 2014-12-25 Genentech, Inc. Treatment of th17 mediated inflammatory diseases
EP2791174B1 (en) 2011-12-15 2018-02-28 F. Hoffmann-La Roche AG Antibodies against human csf-1r and uses thereof
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
CN104684582A (zh) 2012-08-31 2015-06-03 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
CN113350501A (zh) 2014-06-23 2021-09-07 戊瑞治疗有限公司 用结合集落刺激因子1受体(csf1r)的抗体治疗病状的方法
AU2015339306B2 (en) 2014-10-29 2021-07-22 Bristol-Myers Squibb Company Combination therapy for cancer
EA201791421A1 (ru) 2014-12-22 2017-10-31 Файв Прайм Терапьютикс, Инк. Антитела против csf1r для лечения pvns
BR112017020952A2 (pt) 2015-04-13 2018-07-10 Five Prime Therapeutics Inc método de tratamento de câncer, composição e uso da composição
JP7138094B2 (ja) 2016-08-25 2022-09-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト マクロファージ活性化剤と組み合わせた抗ｃｓｆ－１ｒ抗体の間欠投与
JP7304287B2 (ja) 2016-12-22 2023-07-06 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｐｄ－ｌ１／ｐｄ１治療の不成功後の、抗ｐｄ－ｌ１抗体との組み合わせでの抗ｃｓｆ－１ｒ抗体を用いた腫瘍の治療
CN106843149A (zh) * 2017-03-28 2017-06-13 吴小江 一种机械零固件产品加工系统
CA3073531A1 (en) 2017-09-13 2019-03-21 Five Prime Therapeutics, Inc. Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4672108A (en) * 1981-12-07 1987-06-09 Hoffmann-La Roche Inc. Crystalline human leukocyte interferon
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
US4966911A (en) * 1984-11-20 1990-10-30 Washington Research Foundation Immunoregulatory agents
US4847201A (en) * 1985-02-05 1989-07-11 Cetus Corporation DNA encoding for CSF-1 and accompanying recombinant systems
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
JPS62106000A (ja) * 1985-10-30 1987-05-16 Fujitsu Ltd 生体高分子結晶自動作製装置
US4908773A (en) * 1987-04-06 1990-03-13 Genex Corporation Computer designed stabilized proteins and method for producing same
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4881175A (en) * 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5032676A (en) 1986-10-14 1991-07-16 Immunex Corporation Nonglycosylated analogs of human colony stimulating factors
WO1988003173A2 (en) * 1986-10-24 1988-05-05 Cetus Corporation New forms of colony stimulating factor-1
US4929700A (en) * 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
IL86090A (en) * 1987-04-16 1993-03-15 Cetus Oncology Corp Production of purified, biologically active, bacterially produced recombinant human csf-1
US4833233A (en) * 1987-08-20 1989-05-23 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Human serum albumin crystals and method of preparation
ATE111921T1 (de) * 1988-06-03 1994-10-15 Chugai Pharmaceutical Co Ltd Menschlicher kristallinischer granulocyt- koloniestimulierungsfaktor und dessen herstellung.
US5109119A (en) * 1989-06-06 1992-04-28 Schering Corporation Crystalline r-h-gm-csf and method
IE66494B1 (en) * 1989-09-26 1996-01-10 Immunex Corp Granulocyte-colony stimulating factor receptors
JP2975109B2 (ja) * 1989-12-21 1999-11-10 ノボ ノルディスク アクティーゼルスカブ 酵素の結晶化方法
DE69231467T2 (de) * 1991-05-10 2001-01-25 Genentech, Inc. Auswählen von agonisten und antagonisten von liganden

Also Published As

Publication number Publication date
DE69329247D1 (de) 2000-09-21
US6184354B1 (en) 2001-02-06
EP0955365A3 (en) 2000-12-20
EP0668914A1 (en) 1995-08-30
JPH08507916A (ja) 1996-08-27
CA2137793A1 (en) 1993-12-23
JP2004285076A (ja) 2004-10-14
EP0668914B1 (en) 2000-08-16
WO1993025687A1 (en) 1993-12-23
US5866114A (en) 1999-02-02
EP0955365A2 (en) 1999-11-10
CA2137793C (en) 2003-04-22
DE69329247T2 (de) 2001-05-31

Similar Documents

Publication Publication Date Title
DE69329247D1 (de) Kristallisierung von m-csf
PT86648A (pt) Method for the preparation of anti-retroviral compositions containing 3'-azido-2',3'-dideoxyuridine
FI870113A7 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 4,5,6-substioitujenN-(substituoitu-fenyyli)-2-pyrimidiiniamiinien valmistamiseksi
IT8122675A0 (it) Mercaptoacil derivati di varie proline 4 sostituite e relative composizioni utili per il trattamento dell'ipertensione.
FI931370A0 (fi) Kvaeve innehaollande analoger av icke-aromatiska heterocykliska foereningar med en fusionerad ring
IT1222394B (it) Processo per la preparazione di 2,2,6,6 tetrametil 4 piperidilammine
RU93058554A (ru) Способы диастереоселективного синтеза нуклеозидов
ATE71627T1 (de) Bryostatine.
ATE243694T1 (de) 4-mercaptoacetylamino-(2)benzazepinon(3)- derivate, und verwendung als enkephalinase- inhibitoren
HU913792D0 (en) Method for producing serotonine antagonists
PT97478A (pt) Processo de producao de derivados n-(3-fluoro-2-fosfonilmetoxipropilo) de bases puricas e pirimidicas heterociclicas e de composicoes farmaceuticas que os contem
IT1217328B (it) Processo per la metallizzazione di materiali fibrosi
DK0444853T3 (da) Hexahydrobenz(cd)indoler
FI872930A7 (fi) Analogiamenetelmä ripulinvastaisten 4-(bentsoyyliamino)piperidiinibutaaniamidijohdannaisten valmistamiseksi
IT8620796A0 (it) Processo per la preparazione dell'n-dimetilchitosano e suoi impieghi farmacologici.
ATE63543T1 (de) 2-oxindolzwischenprodukte.
DE68918479D1 (de) Menschlicher Hitzeschock-Faktor.
DE3876193D1 (de) Aminomethylderivate von mono- und dithiocarbamaten als schmiermitteladditive.
IT1174473B (it) Procedimento per la produzione di polietelene di bassa densita'lineare
PT90719A (pt) Processo de preparacao de 2-etenil-3,4,5,6-tetra-hidrotieno{4,3,2-ef}{3} benzazepinas substituidas e de composicoes farmaceuticas que as contem
DE59007354D1 (de) Monohydrochlorid und Monomethansulfonat von Amonafide.
FR2595704B1 (fr) Derives de la proline
NO891681D0 (no) Fremgangsmaate for syntese av c5+ hydrokarboner.
ATE114310T1 (de) Alpha-adrenergische rezeptorantagonisten.
DE68903028D1 (de) Verfahren zur chemisch-biologischen entschwefelung von kohle.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties